ProQR and Galapagos Announce Research Collaboration on Fibrosis Targets Using ProQR’s Axiomer® technology Press release LEIDEN, the Netherlands, Jan. 08, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR), today announced that it has entered into a research collaboration agreement with Galapagos N.V. (Euronext & NASDAQ:GLPG). January 08, 2018
ProQR Announces Extraordinary General Meeting of Shareholders Press release LEIDEN, the Netherlands, Dec. December 27, 2017
ProQR Receives Orphan Drug Designation from EMA for Drug Candidate QR-313 for Dystrophic Epidermolysis Bullosa Press release Key Updates November 29, 2017
ProQR to Present at the Annual Piper Jaffray Healthcare Conference Press release LEIDEN, the Netherlands, Nov. November 21, 2017
ProQR Prices Approximately $20 Million Underwritten Public Offering and Concurrent Registered Direct Offering of Ordinary Shares Press release LEIDEN, The Netherlands, Nov. 14, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. November 14, 2017
ProQR Announces Proposed Public Offering of Ordinary Shares Press release LEIDEN, the Netherlands, Nov. November 13, 2017
ProQR Doses First LCA 10 Patient in Clinical Trial of QR-110, ProQR’s Lead Program for Genetic Blindness Press release Key Updates November 13, 2017
ProQR Appoints Thaddeus Dryja, M.D. to Scientific Advisory Board Press release Key Updates November 09, 2017
ProQR to Present at EuroTIDES Conference Press release LEIDEN, The Netherlands, Oct. 31, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. October 31, 2017